Literature DB >> 19165163

Association studies on ghrelin and ghrelin receptor gene polymorphisms with obesity.

Maria Gueorguiev1, Cécile Lecoeur, David Meyre, Michael Benzinou, Charles A Mein, Anke Hinney, Vincent Vatin, Jacques Weill, Barbara Heude, Johannes Hebebrand, Ashley B Grossman, Márta Korbonits, Philippe Froguel.   

Abstract

Ghrelin exerts a stimulatory effect on appetite and regulates energy homeostasis. Ghrelin gene variants have been shown to be associated with metabolic traits, although there is evidence suggesting linkage and association with obesity and the ghrelin receptor (GHSR). We hypothesized that these genes are good candidates for susceptibility to obesity. Direct sequencing identified 12 ghrelin single-nucleotide polymorphisms (SNPs) and 8 GHSR SNPs. The 10 common SNPs were genotyped in 1,275 obese subjects and in 1,059 subjects from a general population cohort of European origin. In the obesity case-control study, the GHSR SNP rs572169 was found to be associated with obesity (P = 0.007 in additive model, P = 0.001 in dominant model, odds ratio (OR) 1.73, 95% confidence interval (1.23-2.44)). The ghrelin variant, g.A265T (rs4684677), showed an association with obesity (P = 0.009, BMI adjusted for age and sex) in obese families. The ghrelin variant, g.A-604G (rs27647), showed an association with insulin levels at 2-h post-oral glucose tolerance test (OGTT) (P = 0.009) in obese families. We found an association between the eating behavior "overeating" and the GHSR SNP rs2232169 (P = 0.02) in obese subjects. However, none of these associations remained significant when corrected for multiple comparisons. Replication of the nominal associations with obesity could not be confirmed in a German genome-wide association (GWA) study for rs4684677 and rs572169 polymorphisms. Our data suggest that common polymorphisms in ghrelin and its receptor genes are not major contributors to the development of polygenic obesity, although common variants may alter body weight and eating behavior and contribute to insulin resistance, in particular in the context of early-onset obesity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165163     DOI: 10.1038/oby.2008.589

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  16 in total

1.  Human longevity and variation in GH/IGF-1/insulin signaling, DNA damage signaling and repair and pro/antioxidant pathway genes: cross sectional and longitudinal studies.

Authors:  Mette Soerensen; Serena Dato; Qihua Tan; Mikael Thinggaard; Rabea Kleindorp; Marian Beekman; Rune Jacobsen; H Eka D Suchiman; Anton J M de Craen; Rudi G J Westendorp; Stefan Schreiber; Tinna Stevnsner; Vilhelm A Bohr; P Eline Slagboom; Almut Nebel; James W Vaupel; Kaare Christensen; Matt McGue; Lene Christiansen
Journal:  Exp Gerontol       Date:  2012-03-03       Impact factor: 4.032

Review 2.  Ghrelin regulation of glucose metabolism.

Authors:  Sarah M Gray; Laura C Page; Jenny Tong
Journal:  J Neuroendocrinol       Date:  2019-04-03       Impact factor: 3.627

3.  Association of A-604G ghrelin gene polymorphism and serum ghrelin levels with the risk of obesity in a mexican population.

Authors:  Iris Monserrat Llamas-Covarrubias; Mara Anaís Llamas-Covarrubias; Erika Martinez-López; Eloy Alfonso Zepeda-Carrillo; Edgar Alfonso Rivera-León; Beatriz Palmeros-Sánchez; Juan Luis Alcalá-Zermeño; Sergio Sánchez-Enríquez
Journal:  Mol Biol Rep       Date:  2017-06-09       Impact factor: 2.316

4.  Uncoupling protein-2 decreases the lipogenic actions of ghrelin.

Authors:  Zane B Andrews; Derek M Erion; Rudolph Beiler; Charles S Choi; Gerald I Shulman; Tamas L Horvath
Journal:  Endocrinology       Date:  2010-02-26       Impact factor: 4.736

5.  Association of ghrelin receptor promoter polymorphisms with weight loss following Roux-en-Y gastric bypass surgery.

Authors:  Michelle E Matzko; George Argyropoulos; G Craig Wood; Xin Chu; Roger J M McCarter; Christopher D Still; Glenn S Gerhard
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

Review 6.  Ghrelin receptor signaling: a promising therapeutic target for metabolic syndrome and cognitive dysfunction.

Authors:  Wei-na Cong; Erin Golden; Nick Pantaleo; Caitlin M White; Stuart Maudsley; Bronwen Martin
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

7.  Family and population-based studies of variation within the ghrelin receptor locus in relation to measures of obesity.

Authors:  Anette P Gjesing; Lesli H Larsen; Signe S Torekov; Irena Aldhoon Hainerová; Rahul Kapur; Anders Johansen; Anders Albrechtsen; Sylvia Boj; Birgitte Holst; Angela Harper; Søren A Urhammer; Knut Borch-Johnsen; Charlotta Pisinger; Søren M Echwald; Hans Eiberg; Arne Astrup; Jan Lebl; Jorge Ferrer; Thue W Schwartz; Torben Hansen; Oluf Pedersen
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

8.  Polymorphisms of genes coding for ghrelin and its receptor in relation to colorectal cancer risk: a two-step gene-wide case-control study.

Authors:  Daniele Campa; Barbara Pardini; Alessio Naccarati; Ludmila Vodickova; Jan Novotny; Verena Steinke; Nils Rahner; Elke Holinski-Feder; Monika Morak; Hans K Schackert; Heike Görgens; Judith Kötting; Beate Betz; Matthias Kloor; Christoph Engel; Reinhard Büttner; Peter Propping; Asta Försti; Kari Hemminki; Roberto Barale; Pavel Vodicka; Federico Canzian
Journal:  BMC Gastroenterol       Date:  2010-09-28       Impact factor: 3.067

9.  Heterozygosity for the rs696217 SNP in the Preproghrelin Gene Predicts Weight Loss After Bariatric Surgery in Severely Obese Individuals.

Authors:  Edoardo Vitolo; Eleonora Santini; Marta Seghieri; Livia Giannini; Fabio Coppedè; Chiara Rossi; Angela Dardano; Anna Solini
Journal:  Obes Surg       Date:  2017-04       Impact factor: 4.129

10.  Ghrelin influences novelty seeking behavior in rodents and men.

Authors:  Caroline Hansson; Rozita H Shirazi; Jakob Näslund; Heike Vogel; Corinna Neuber; Göran Holm; Henrik Anckarsäter; Suzanne L Dickson; Elias Eriksson; Karolina P Skibicka
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.